$LIFE

Ethos Technologies Inc. (LIFE): Results of Operations and Financial Condition

Ethos Technologies Inc. (LIFE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ethos Reports Second Quarter Fiscal Year 2026 Financial Results • Q2 Revenue grew 113% year-over-year to $190 million • Q2 Direct Channel Revenue grew 131% year-over-year to $116 million • Q2 Third-Party Revenue grew 90% year-over-year to $73 million • Board of Direc

Original reporting
Published Aug 3, 2026, 8:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$LIFE
Bullish
high confidence
Mentioned
$LIFE
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LIFEBullishHigh
01

Why it matters

Traders can update valuation and positioning based on the disclosed Q3 and FY2026 revenue and Adj. EBITDA ranges, and the new $100M Class A buyback authorization.

02

Market read

Fresh earnings and guidance ranges plus a buyback authorization are immediate repricing inputs for LIFE.

03

What to watch

Non-GAAP metrics exclude items with high variability; GAAP reconciliation details are not fully shown in the excerpt, so investors may scrutinize sustainability of margins and cash conversion.

Relevance 7/10Novelty 9/10Timing: after-hours filing, guidance and buyback authorization disclosed today

Background

This is an SEC Form 8-K (Item 2.02) with Ethos’ Q2 FY2026 results and forward guidance, filed the same day as the press release.

Company-level read

Ticker impact

$LIFEBullishHigh confidence
Context

Ethos reported Q2 FY2026 revenue up 113% YoY to $189.6M, plus Q3 revenue guidance of $160M to $164M and Adj. EBITDA $23M to $25M.

Expected impact

Likely positive near-term bias if investors view guidance as credible and margins/EBITDA trajectory as sustainable.

Evidence & confidence

The filing discloses fresh, decision-relevant datapoints: Q2 results, forward guidance ranges, and a new buyback authorization, all of which can reprice expectations immediately.

Market effects

Reinforces demand and unit-economics momentum in life insurance technology distribution, potentially supporting sentiment for insurtech peers.

Limited direct regional spillover; primarily US-listed insurtech sentiment.

Low global macro linkage; mostly company-specific guidance and capital return.

Counterpoint

Revenue growth is strong, but average revenue per unit fell 8% YoY, which could signal mix shift or pricing pressure that may cap future profitability.

Key entities

  • Ethos Technologies Inc.

    Nasdaq-listed life insurance technology company reporting Q2 FY2026 results, issuing Q3 and FY2026 guidance, and authorizing a $100M share repurchase program.

  • Board of Directors

    Authorized a share repurchase program of up to $100 million of Ethos Class A common stock.

  • Peter Colis

    CEO and Co-Founder quoted on growth momentum and policy activations.

Related articles

$LIFEMed

Ethos (LIFE) Grows Revenue 113% While Margins Quietly Compress

Ethos Technologies (LIFE) reported Q2 revenue growth of 113% to $189.6M, with new policies up 133%. Gross profit margin was 98%, but net income rose only 5% to $19.5M. The company authorized a $100M stock buyback. Q3 revenue guidance is $160M-$164M, and full-year guidance is $727M-$731M. Margins compressed, with GAAP net loss of $146.9M for H1 2026 due to stock-based compensation.

$LIFEMedAI 9/10

Ethos (LIFE) Q2 2026 Earnings Call Transcript

Ethos Technologies (LIFE) reported Q2 2026 revenue of $189.6 million, up 113% Y/Y, with direct revenue $116.5 million (+131%) and third-party revenue $73.1 million (+90%). Adjusted EBITDA was $35.2 million (19% margin). Net income was $19.5 million. Full-year 2026 guidance: revenue $727-$731 million and adjusted EBITDA $119-$123 million. Up to $100 million Class A repurchase authorized.

$LIFEMed

Top SMid Cap Pick: Ethos Technologies Leads Citi’s Rankings

Citi analyst Ronald Josey named Ethos Technologies (LIFE) his top SMID-cap pick after the company’s Q2 results. Activated policies growth accelerated to 133% YoY, with 107,800 net activated policies. Revenue rose to $189.6M (+113% YoY). Ethos raised 2026 revenue guidance to $727M-$731M and adjusted EBITDA to $119M-$123M. Citi lifted its price target to $33 and kept Buy/High Risk.

$EQIXMedAI 8/10

Equinix Is Doubling Down on AI Data Centers. How to Play EQIX Stock Here

Equinix (EQIX) reported Q2 revenue of $2.63B, up 16% YoY, beating estimates. AFFO was $11.78/share, up 19% YoY. The company raised full-year guidance and unveiled a multi-year growth plan. EQIX stock has surged 34% over the past year and offers a 1.98% dividend yield. Analysts rate it a 'Strong Buy' with an average price target of $1,232.19.